Cullinan Oncology, Inc. (CGEM) Stock Forecast
CGEM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.92 / 5 from 12 analysts
- Price target
- $33.45 average of analyst targets
- Upside to target
- +158.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.79
- 52-week range
- $7.19 – $22.95
CGEM analyst ratings
12 analystsNumber of analysts at each rating.
CGEM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CGEM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.84 | −$1.04 | −$0.71 | −$0.77 | −9.1% | 9 |
| Current fiscal year (2026) | −$3.13 | −$3.79 | −$1.85 | −$3.36 | +7.0% | 9 |
| Next fiscal year (2027) | −$2.52 | −$3.93 | −$1.25 | −$3.13 | +19.5% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CGEM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $13.9M | $0 | $104.0M | 0.0% | 10 |
| Next fiscal year (2027) | $52.8M | $0 | $167.7M | +280.4% | 11 |
CGEM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CGEM revenue: reported and forecast
CGEM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.86 | −$0.86 | −$0.85 | −$0.84 | −$0.84 | −2.6% | 2 up · 0 down |
| Current fiscal year (2026) | −$3.00 | −$3.00 | −$3.17 | −$3.13 | −$3.13 | +4.3% | 3 up · 0 down |
| Next fiscal year (2027) | −$2.53 | −$2.53 | −$2.71 | −$2.75 | −$2.52 | −0.5% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CGEM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CGEM beat in 9 of 12.
What analysts expect from CGEM
12 analysts cover Cullinan Oncology; their consensus rating is strong buy (4.92 on a 1–5 scale, where 5 is a strong buy). The average price target is $33.45, 158.7% above the latest close of $12.93. Analysts expect earnings of −$3.13 per share for 2026, +7.0% from a year earlier. For 2027 the average estimate is −$2.52 per share on revenue of $52.8 million. Cullinan Oncology beat the EPS estimate in 9 of the last 12 quarters.
Related: CGEM income statement, CGEM key metrics, CGEM chart. See the CGEM stock overview for the latest quote and news.
CGEM forecast FAQ
What is Cullinan Oncology's price target?
The average analyst price target for Cullinan Oncology is $33.45, 158.7% above the latest close of $12.93.
Is Cullinan Oncology a buy, hold or sell?
Of 12 analysts covering Cullinan Oncology, 11 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cullinan Oncology's EPS forecast?
Analysts forecast −$3.13 per share for 2026 (range −$3.79 to −$1.85); for 2027 the estimate is −$2.52.
What is Cullinan Oncology's revenue forecast?
The average revenue estimate for 2026 is $13.9 million, growth of 0.0%; for 2027 it is $52.8 million.
When does Cullinan Oncology report earnings?
Cullinan Oncology is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.79.
Does Cullinan Oncology usually beat earnings estimates?
Cullinan Oncology reported EPS at or above the analyst estimate in 9 of the last 12 quarters.